PharmaEngine begins Phase Ib/II trial of PEP503 to treat head and neck cancer

PharmaEngine has announced that the first patient has been dosed in a Phase Ib/II trial of PEP503 (NBTXR3) of head and neck squamous cell carcinoma (HNSCC) at Keelung Chang Gung Memorial Hospital (Lovers Lake Branch) in Keelung, Taiwan.

Source: Drug Development Technology - October 20, 2016 Category: Pharmaceuticals Source Type: news